Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Aug 9;39(8):1037-1038.
doi: 10.1016/j.ccell.2021.06.015. Epub 2021 Jun 26.

Immunogenicity of a heterologous COVID-19 vaccine after failed vaccination in a lymphoma patient

Joshua A Hill  1 , Chaitra S Ujjani  2 , Alexander L Greninger  3 , Mazyar Shadman  2 , Ajay K Gopal  2
Affiliations
Comment

Immunogenicity of a heterologous COVID-19 vaccine after failed vaccination in a lymphoma patient

Joshua A Hill et al. Cancer Cell. .
No abstract available

Keywords: COVID-19; SARS-CoV-2; booster; hematologic malignancy; vaccine.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests J.A.H. received consulting fees from Gilead Sciences, Amplyx, Allovir, Allogene therapeutics, CRISPR therapeutics, and Takeda and research funding from Takeda, Allovir, Karius, and Gilead Sciences. C.S.U reports consulting fees from Atara, AstraZeneca, Epizyme, Abbvie, PYC, Genentech, ACDT, and TG therapeutics and research funding from loxo, PYC, AstraZeneca, and Adaptive Biotechnologies. A.L.G reports central testing contracts from Abbott, research grants from Gilead and Merck, and spouse’s salary from LabCorp. M.S reports consulting, advisory boards, steering committees, or data safety monitoring committees for Abbvie, Genentech, AstraZeneca, Sound Biologics, Pharmacyclics, Beigene, Bristol Myers Squibb, Morphosys, TG Therapeutics, Innate Pharma, Kite Pharma, Adaptive Biotechnologies, Epizyme, Eli Lilly, and Atara Biotherapeutics and research funding from Mustang Bio, Celgene, Bristol Myers Squibb, Pharmacyclics, Gilead, Genentech, Abbvie, TG Therapeutics, Beigene, AstraZeneca, Sunesis, Atara Biotherapeutics, and GenMab. A.K.G reports research funding from Seagen, Bristol Myers Squibb, Pharmacyclics, Gilead, Genentech, AstraZeneca, Pfizer, Teva, Takeda, Acrotec, IgM, I-Mab, Agios, and Merck and honoraria and/or consulting fees from Abbvie, Genentech, janssen, AstraZeneca, Pharmacyclics, Bristol Myers Squibb, Amgen, Morphosys, TG Therapeutics, Kite Pharma, Adaptive, SeaGen, Epizyme, Kite, Gilead, ADCT, Incyte, Karyopharm, Actinium, Asana bio, Nurix, and Aptevo.

Comment on

  • Seroconversion rates following COVID-19 vaccination among patients with cancer.
    Thakkar A, Gonzalez-Lugo JD, Goradia N, Gali R, Shapiro LC, Pradhan K, Rahman S, Kim SY, Ko B, Sica RA, Kornblum N, Bachier-Rodriguez L, McCort M, Goel S, Perez-Soler R, Packer S, Sparano J, Gartrell B, Makower D, Goldstein YD, Wolgast L, Verma A, Halmos B. Thakkar A, et al. Cancer Cell. 2021 Aug 9;39(8):1081-1090.e2. doi: 10.1016/j.ccell.2021.06.002. Epub 2021 Jun 5. Cancer Cell. 2021. PMID: 34133951 Free PMC article.
  • Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer.
    Addeo A, Shah PK, Bordry N, Hudson RD, Albracht B, Di Marco M, Kaklamani V, Dietrich PY, Taylor BS, Simand PF, Patel D, Wang J, Labidi-Galy I, Fertani S, Leach RJ, Sandoval J, Mesa R, Lathrop K, Mach N, Shah DP. Addeo A, et al. Cancer Cell. 2021 Aug 9;39(8):1091-1098.e2. doi: 10.1016/j.ccell.2021.06.009. Epub 2021 Jun 18. Cancer Cell. 2021. PMID: 34214473 Free PMC article.

References

    1. Addeo A., Shah P.K., Bordry N., Hudson R.D., Albracht B., Di Marco M., Kaklamani V., Dietrich P.-Y., Taylor B.S., Simand P.-F., et al. Immunogenicity of SARS-CoV-2 messenger RNA Vaccines in Patients with Cancer. Cancer Cell. 2021;39:1091–1098. - PMC - PubMed
    1. Bradley B.T., Bryan A., Fink S.L., Goecker E.A., Roychoudhury P., Huang M.-L., Zhu H., Chaudhary A., Madarampalli B., Lu J.Y.C., et al. MedRxiv; 2021. Anti-SARS-CoV-2 antibody levels are concordant across multiple platforms but are not fully predictive of sterilizing immunity. - DOI - PMC - PubMed
    1. Cardell K., Åkerlind B., Sällberg M., Frydén A. Excellent response rate to a double dose of the combined hepatitis A and B vaccine in previous nonresponders to hepatitis B vaccine. J. Infect. Dis. 2008;198:299–304. - PubMed
    1. Crawford K.H.D., Eguia R., Dingens A.S., Loes A.N., Malone K.D., Wolf C.R., Chu H.Y., Tortorici M.A., Veesler D., Murphy M., et al. Protocol and reagents for pseudotyping lentiviral particles with SARS-CoV-2 spike protein for neutralization assays. Viruses. 2020;12:E513. - PMC - PubMed
    1. Herishanu Y., Avivi I., Aharon A., Shefer G., Levi S., Bronstein Y., Morales M., Ziv T., Shorer Arbel Y., Scarfò L., et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood. 2021;137:3165–3173. - PMC - PubMed

Substances